Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy
Miia Kivipelto,
Craig W Ritchie,
David Scott,
Josip Car,
Heather Ward,
Karen Ritchie,
Martin Cohn,
Geraint Price,
Susan Baker,
Nzeera Ketter,
Chinedu T. Udeh-Momoh,
Tamlyn Watermeyer,
Celeste A de Jager Loots,
Natalia Reglinska-Matveyev,
Michael Ropacki,
Michael Fogle,
Nandini Raghavan,
Michael Arrighi,
Robert Brashear,
Jianing Di,
Parthenia Giannakopoulou,
Catherine Robb,
Darina Bassil,
Heather McLellan-Young,
Jennifier Crispin,
Kristina Lakey,
Curry Lisa,
Yellappa Chowdary Seemulamoodi,
Dimitra Kafetsouli,
Dinithi Perera,
Luc Bracoud,
Ziad Saad,
Gerald Novak,
Lefkos Middleton
Affiliations
Miia Kivipelto
1 Division of Clinical Geriatrics, NVS, Karolinska Institutet, Solna, Sweden
Craig W Ritchie
6 Centre for Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
David Scott
Bone and Muscle Health Research Group, School of Clinical Sciences at Monash Health, Monash Medical Centre, Victoria, Australia
Josip Car
Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
Heather Ward
2 Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester, UK
Karen Ritchie
U1061 Neuropsychiatry, INSERM, University of Montpellier, Montpellier, France
Martin Cohn
Department of Medicine, The Hillingdon Hospitals NHS Foundation Trust
Geraint Price
Central and North West London NHS Foundation Trust, London, UK
Susan Baker
Center for Injury Research and Policy, Johns Hopkins School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA
Nzeera Ketter
1Janssen Research & Development, South San Francisco, California, USA
Chinedu T. Udeh-Momoh
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Tamlyn Watermeyer
Department of Psychology, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK
Celeste A de Jager Loots
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Natalia Reglinska-Matveyev
Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
Michael Ropacki
Janssen Research and Development, Fremont, California, USA
Michael Fogle
Janssen Research and Development LLC, Titusville, New Jersey, USA
Nandini Raghavan
Janssen Research and Development LLC, Titusville, New Jersey, USA
Michael Arrighi
Janssen Research and Development, Fremont, California, USA
Robert Brashear
Janssen Alzheimer Immunotherapy Research and Development LLC, South San Francisco, California, USA
Jianing Di
Department of Biostatistics, Janssen Research and Development Shanghai, Shanghai, China
Parthenia Giannakopoulou
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Catherine Robb
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Darina Bassil
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Heather McLellan-Young
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Jennifier Crispin
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Kristina Lakey
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Curry Lisa
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Yellappa Chowdary Seemulamoodi
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Dimitra Kafetsouli
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Dinithi Perera
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Luc Bracoud
BioClinica Inc, Lyon, France
Ziad Saad
Janssen Research and Development, Fremont, California, USA
Gerald Novak
Janssen Research and Development LLC, Titusville, New Jersey, USA
Lefkos Middleton
Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
Introduction The Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy (CPSS), sponsored by Janssen Pharmaceutical Research & Development LLC, is an Alzheimer’s disease (AD) biomarker enriched observational study that began 3 July 2015 CPSS aims to identify and validate determinants of AD, alongside cognitive, functional and biological changes in older adults with or without detectable evidence of AD pathology at baseline.Methods and analysis CPSS is a dual-site longitudinal cohort (3.5 years) assessed quarterly. Cognitively normal participants (60–85 years) were recruited across Greater London and Edinburgh. Participants are classified as high, medium (amnestic or non-amnestic) or low risk for developing mild cognitive impairment–Alzheimer’s disease based on their Repeatable Battery for the Assessment of Neuropsychological Status performance at screening. Additional AD-related assessments include: a novel cognitive composite, the Global Preclinical Alzheimer’s Cognitive Composite, brain MRI and positron emission tomography and cerebrospinal fluid analysis. Lifestyle, other cognitive and functional data, as well as biosamples (blood, urine, and saliva) are collected. Primarily, study analyses will evaluate longitudinal change in cognitive and functional outcomes. Annual interim analyses for descriptive data occur throughout the course of the study, although inferential statistics are conducted as required.Ethics and dissemination CPSS received ethical approvals from the London—Central Research Ethics Committee (15/LO/0711) and the Administration of Radioactive Substances Advisory Committee (RPC 630/3764/33110) The study is at the forefront of global AD prevention efforts, with frequent and robust sampling of the well-characterised cohort, allowing for detection of incipient pathophysiological, cognitive and functional changes that could inform therapeutic strategies to prevent and/or delay cognitive impairment and dementia. Dissemination of results will target the scientific community, research participants, volunteer community, public, industry, regulatory authorities and policymakers. On study completion, and following a predetermined embargo period, CPSS data are planned to be made accessible for analysis to facilitate further research into the determinants of AD pathology, onset of symptomatology and progression.Trial registration number The CHARIOT:PRO SubStudy is registered with clinicaltrials.gov (NCT02114372). Notices of protocol modifications will be made available through this trial registry.